#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16720	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2078	797.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1619	1619	T	904	T,C	792,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16720	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2078	797.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1353	1353	C	1012	C	907	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30542	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3513	866.2	0	.	n	.	0	T695C	SNP	695	695	T	1016	1016	C	935	C,T	845,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30542	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3513	866.2	0	.	n	.	0	A1223G	SNP	1223	1223	A	1544	1544	G	1060	G,A	739,234	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30542	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3513	866.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2292	2292	C	974	C	864	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30542	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3513	866.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2918	2918	T	990	T,C	899,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30542	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3513	866.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2366	2366	A	927	A	860	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	30542	23S	2890	2890	99.86	23S.l6.c17.ctg.1	3513	866.2	0	HET	.	.	.	G1337A	.	1337	1337	G	1658	1658	G	1140	G,A	757,246	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2458	folP	855	855	100.0	folP.l6.c30.ctg.1	1546	158.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1024	1026	AGC	232;231;235	A;G;C	208;204;210	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	6370	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3309	191.8	1	SNP	p	S91F	1	.	.	271	273	TTC	525	527	TTC	218;215;218	T;T;C	196;195;198	gyrA.WHO_Z_01155:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	6370	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3309	191.8	1	SNP	p	N95G	0	.	.	283	285	AAC	537	539	AAC	227;227;227	A;A;C	201;201;201	gyrA.WHO_Z_01155:1:1:N95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_Z_01155	gyrA.WHO_Z_01155	1	1	27	6370	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3309	191.8	1	SNP	p	D95N	1	.	.	283	285	AAC	537	539	AAC	227;227;227	A;A;C	201;201;201	gyrA.WHO_Z_01155:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1788	mtrR	633	633	99.37	mtrR.l15.c30.ctg.1	1389	128.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	525	527	ACC	199;201;201	A;C;C	180;186;184	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1788	mtrR	633	633	99.37	mtrR.l15.c30.ctg.1	1389	128.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	723	725	CAC	231;233;233	C;A;C	203;201;204	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	1788	mtrR	633	633	99.37	mtrR.l15.c30.ctg.1	1389	128.4	1	SNP	p	G45D	0	.	.	133	135	GGC	543	545	GGC	215;216;219	G,T;G;C	186,1;190;193	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	964	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	894	106.3	0	.	n	.	0	A197.	DEL	197	197	A	523	523	A	223	A	208	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6014	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2929	204.7	1	SNP	p	S87I	1	S87I	NONSYN	259	261	AGT	536	538	ATT	259;256;259	A;T;T	234;234;239	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6014	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2929	204.7	0	.	p	.	0	T518_Q519insR	INS	1552	1552	A	1830	1830	C	218	C	195	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6014	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2929	204.7	1	SNP	p	D86N	0	.	.	256	258	GAC	533	535	GAC	260;258;261	G;A;C	235;230;237	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	539	6014	parC	2304	2304	99.83	parC.l15.c4.ctg.1	2929	204.7	1	SNP	p	S88P	0	.	.	262	264	TCC	539	541	TCC	258;260;262	T;C;C	238;236;241	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5338	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2680	198.7	0	.	p	.	0	T35I	NONSYN	103	105	ACA	392	394	ATA	197;202;201	A;T;A	180;184;181	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5338	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2680	198.7	0	.	p	.	0	D437N	NONSYN	1309	1311	GAT	1598	1600	AAT	273;275;272	A;A;T,A	244;244;241,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	5338	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2680	198.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1517	1519	GGC	281;278;276	G;G;C,T	244;239;234,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1188	1190	GCA	248;249;252	G;C;A	224;226;228	penA.18.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1191	1193	ATC	252;250;242	A;T;C,G	230;227;220,1	penA.18.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1203	1205	GTG	235;234;234	G;T;G	217;209;211	penA.18.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1203	1205	GTG	235;234;234	G;T;G	217;209;211	penA.18.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1707	1709	ACC	232;234;236	A;C;C,T	206;210;210,1	penA.18.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1761	1763	ACG	214;216;216	A,C;C;G,A	170,1;175;170,1	penA.18.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1761	1763	ACG	214;216;216	A,C;C;G,A	170,1;175;170,1	penA.18.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1884	1886	AGC	205;205;205	A;G;C	186;185;186	penA.18.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1893	1895	GGC	201;196;196	G;G;C	180;176;174	penA.18.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.18.001	penA.18.001	1	1	27	4416	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2388	183.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1911	1913	CCG	172;174;175	C,G,T;C;G	129,2,1;135;135	penA.18.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6232	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3210	193.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1602	1604	CCG	244;244;243	C;C;G	220;225;222	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2660	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1810	146.5	0	.	p	.	0	A17T	NONSYN	49	51	GCA	354	356	ACA	162;164;160	A;C;A	146;149;146	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2660	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1810	146.5	0	.	p	.	0	S22G	NONSYN	64	66	AGC	369	371	GGC	161;160;166	G;G;C	141;139;140	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2660	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1810	146.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	551	551	C	210	C	178	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	0	.	p	.	0	T26A	NONSYN	76	78	ACC	381	383	GCC	260;261;267	G;C;C	239;241;247	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	417	419	GAA	279;275;280	G;A;A	253;248;255	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	705	707	GAT	247;247;252	G;A;T	224;220;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	828	830	TCA	244;245;246	T;C;A	223;224;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	957	959	GTC	257;260;260	G,C;T;C	229,1;231;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	0	.	p	.	0	R258H	NONSYN	772	774	CGT	1077	1079	CAT	231;231;227	C;A;T	206;208;207	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	1	SNP	p	G120K	1	.	.	358	360	AAG	663	665	AAG	258;259;259	A;A;G	236;237;237	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	1	SNP	p	D121N	0	.	.	361	363	GAC	666	668	GAC	260;261;260	G;A;C	239;239;238	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3018	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1651	182.2	1	SNP	p	A121D	1	.	.	361	363	GAC	666	668	GAC	260;261;260	G;A;C	239;239;238	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10650	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4985	213.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1052	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	974	107.7	1	SNP	p	V57M	1	.	.	169	171	ATG	499	501	ATG	232;232;233	A;T;G	207;212;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
